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3066Introduction: Advances in highly active antiretroviral therapy have dramatically improved the lifespan of
patients infected with human immunodeficiency virus (HIV). We sought to examine the impact of HIV status
on outcomes in patients undergoing cardiovascular surgery.
Methods:We identified 5,621,817 patients who underwent coronary artery bypass graft (CABG), valve, aortic,
or other cardiovascular surgery between 1998 and 2009 from the Nationwide Inpatient Sample. Of these,
9771 (0.17%) patients were seropositive for HIV. Using multivariable logistic regression modeling and
1:1 propensity-score matching, we determined the influence of HIV infection on outcomes.
Results: The percentage of HIVþ patients undergoing cardiovascular surgery increased significantly from
0.09% to 0.23%. HIVþ patients were more often male, black, younger than 55 years of age, and on Medicaid,
and they were more likely to undergo valve and other cardiovascular surgeries, but less likely to have CABG.
Among propensity-matched pairs, patients with HIV were at no increased risk for in-patient mortality.
HIVþ patients weremore likely to receive a blood transfusion and have any postoperative complication. Patients
with HIV were less likely to have a postoperative stroke. Rates of pneumonia, renal complications, and wound
infection were similar between the groups. The median length of stay and mean total cost were not different
between the groups. Factors that predicted in-hospital death in HIVþ patients included metastatic cancer,
coagulopathy, renal failure, and aortic, other, or combined surgical procedure.
Conclusions: Cardiovascular surgery can be performed safely on patients with HIV with no increased hospital
mortality and only minimal increased need for blood transfusion. (J Thorac Cardiovasc Surg 2014;148:3066-75)Advances in highly active antiretroviral therapy (HAART)
have dramatically improved the prognosis of patients posi-
tive for human immunodeficiency virus (HIV).1 HAART
has extended the lives of HIVþ patients by decreasing viral
load and increasing CD4 T cell counts.2 The combination of
immune reconstitution, improved antibiotic prophylaxis,
and increased access to care has drastically ameliorated
the incidence of life-threatening opportunistic infections in
HIVþ patients.3 Despite an actual increase in the prevalence
of HIV infection, the overall morbidity andmortality of HIV
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The Journal of Thoracic and Cardiovascular SurHIVþ patients to live much longer with what is now consid-
ered a chronic disease. A growing population of patients
with HIV is now developing cardiovascular disease. Tradi-
tional cardiovascular risk factors such as hypertension,
hyperlipidemia, and metabolic syndrome are known to be
exacerbated by antiretroviral drugs.4-6 HIVþ patients on
HAART have an increased risk of developing coronary
artery disease (CAD) and myocardial infarction (MI).7-9
Accordingly, the number of HIVþ patients requiring some
form of cardiovascular surgery is increasing.
Outcomes of cardiovascular surgery in HIVþ patients
have been described in smaller patient series. Cardiovascu-
lar surgery using cardiopulmonary bypass does not seem to
accelerate immunodeficiency or produce adverse effects
in patients with HIV.10 Although many studies have shown
that cardiovascular surgery in HIVþ patients can be
performed safely with acceptable mortality, there seems
to be higher rates of complications in this patient
population.11 The outcomes from a population-based
perspective, however, are still unknown. The aim of this
study was to examine the impact of HIV infection on
mortality, complications, length of stay, and cost in patients
undergoing cardiovascular surgery.
PATIENTS AND METHODS
Data
The Nationwide Inpatient Sample (NIS) Healthcare Cost Utilization
Project (HCUP) database was queried from 1998 to 2009 for patientsgery c December 2014
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CAD ¼ coronary artery disease
CCS ¼ Clinical Classifications Software
CI ¼ confidence interval
HAART ¼ highly active antiretroviral therapy
HCUP ¼ Healthcare Cost Utilization Project
HIV ¼ human immunodeficiency virus
MI ¼ myocardial infarction
NIS ¼ Nationwide Inpatient Sample
OR ¼ odds ratio
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tion of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
diagnosis and procedure codes. The NIS is the largest all-payer inpatient
discharge database. The patients represent a 20% stratified sample of all
discharges occurring in a given year from approximately 1000 hospitals
in 24 to 45 states (depending on the year of the study). The database
contains information on about 8 million discharges per year. Individual
entries in the database contain information on demographics, comorbidity,
hospital charges, length of stay, procedures, outcomes, and discharge.
Discharge weights are provided, which allow extraction of nation-level
estimates from the unweighted database information. Weighted estimates
are reported throughout. Patients who underwent cardiovascular surgery
were identified using the preexisting Clinical Classifications Software
(CCS) procedure codes 43 (heart valve surgery), 44 (coronary bypass
surgery), 49 (other operating room heart procedure), and 52 (aortic
surgery).12 Furthermore, we excluded certain procedures within CCS 49
that we felt were not necessarily cardiovascular surgeries if they were
the primary procedure: ICD-9-CM 37.34 (excision of other heart lesion
via catheter), 37.61 (insertion of intra-aortic balloon pump), 37.68
(insertion of percutaneous heart assist device), 37.90 (insertion of left atrial
appendage device), 37.91 (open chest cardiac massage), and 37.99
(removal of pacemaker device). Patients with a history of HIV infection
were identified using the predefined CCS diagnosis code 5. The patients
who underwent cardiovascular surgery without a diagnosis of HIV
infection were used as a comparison group. Patients less than 18 and
more than 100 years old were excluded. The database provides
de-identified, publically available data and use does not require institu-
tional review board approval.
Population
Data on 5,631,589 patients who underwent cardiovascular surgery were
available in the NIS for analysis. There were 9771 (0.17%) patients who
had a diagnosis of HIV infection.
Outcomes
The outcomes analyzed for each hospitalization were in-hospital
mortality, length of stay, discharge disposition, hospital charges and cost,
and complications. The complications were identified through secondary
ICD-9-CM codes and included stroke, blood transfusion, wound infection,
acute renal failure, pneumonia, and the composite outcome of any compli-
cation. Hospital resource consumption was evaluated by hospitalization
charges and hospitalization cost. The categories of disposition were routine
discharge, transfer to another inpatient facility, transfer to another type of
facility (including acute care and skilled nursing facilities), and home
health care. Total charges represent the amount hospitals billed for services
and do not include professional fees. Total costs were derived from total
charges using a cost-to-charge ratio created by HCUP that is based onThe Journal of Thoracic and Caraccounting reports from the Centers for Medicare and Medicaid Services.
Hospital costs tend to better estimate resource use because hospital charges
often reflect payor policies and other factors unrelated to resource use. Cost
was calculated by multiplying total charges with the hospital-specific
cost-to-charge ratio. Costs were adjusted for inflation and converted to
2009 US dollars using the appropriate Consumer Price Index.
Covariables
We considered demographics, comorbidities, insurance status, hospital
characteristics, and the region where procedures were performed. Patient-
level variables included age, sex, race, and insurance status. Race/ethnicity
was categorized as white, black, Hispanic, and other/missing. Certain states
do not document race on discharge records, and thus race is missing for
approximately 25% of the studypopulation. Insurance statuswas categorized
as Medicare, Medicaid, private insurance, uninsured, and other based on the
primary payer listed on the discharge record. Comorbidities for risk
adjustment were derived from secondary ICD-9-CM diagnosis codes using
a modification of the approach developed by Elixhauser and colleagues.13
We excluded several of the 30 comorbidities because they were either the
focus of the study (HIV) or were too few in number (eg, pulmonary
circulation disorders, chronic peptic ulcer disease). A hospital was
considered to be a teaching hospital if it had a residency program approved
by theAmericanMedicalAssociation,wasamemberof theCouncil ofTeach-
ing Hospitals, or had a ratio of full-time equivalent interns and residents to
beds of 0.25 or higher. Hospital region was classified by the US Census
Bureau as northeast, midwest, south, or west. Hospital bed size was
classified as small, medium, or large, based on an algorithm developed by
HCUP. Surgical procedurewas categorized as isolated coronary artery bypass
graft (CABG), isolated valve repair or replacement, isolated aortic surgery,
other operative heart surgery, or a combination of 2 or more of these.
Statistical Analysis
The mean, median, and standard deviation were calculated for
all continuous outcomes, and frequency counts and percentages
for categorical outcomes. Appropriate statistical tests were used for
categorical (c2 test) and continuous (Student t test) outcomes to compare
unadjusted differences by previous transplant status. All data included in
the present study are weighted data from the NIS database.Matching
Propensity scores, or the conditional probability of having a history of
HIV infection, were estimated for each patient using a multivariable
logistic regression model in which the presence of HIV was the dependent
variable and patient demographics, payer status, comorbidities, hospital
characteristics, and procedure type were the independent variables. The
purpose of the propensity score was to balance the covariables for patients
with and without HIV infection in order to assess outcomes without
influence from known factors. To match those with and without HIV
infection, we used a 1:1 greedy matching algorithm with a caliper of 0.2
times the standard deviation of the linear propensity score. The balance
of covariables before and after matching was assessed by calculating the
standardized differences between those with and without HIV.14 We also
performed c2 tests for all covariables before matching, and the McNemar
test in the matched sample. Propensity matching resulted in 1633 pairs of
patients with and without a history of HIV who were well-matched with
respect to demographics, comorbidities, surgical procedures, and
institutional characteristics (ie, region, teaching status, and so forth)
(Figure 1). After matching, we compared outcomes between the HIVþ
group and the HIV controls using difference in means with paired t tests
for costs and length of stay, and conditional logistic regression for mortality
and complication outcomes.
All analyses were performed using the SAS System for Unix, version
9.2 (SAS Institute, Inc, Cary, NC).diovascular Surgery c Volume 148, Number 6 3067
FIGURE 1. Covariance balance plot for patients with and without HIV before and after propensity matching. CABG, Coronary artery bypass graft.
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DRESULTS
Patient Characteristics
Over the course of the study, the percentage of patients
with HIV undergoing cardiac surgery increased signifi-
cantly from 0.09% to 0.23% (P< .001). The association3068 The Journal of Thoracic and Cardiovascular Surbetween demographic variables and HIV status is shown
in Table 1. Patients with HIV were more often male (80%
vs 68%), black (33% vs 5%), and Hispanic (9% vs 4%),
and less likely to be white (4% vs 61%) (all P< .001).
HIVþ patients were also younger with a mean age ofgery c December 2014
TABLE 1. Distribution of operative and demographic characteristics
according to HIV status
Characteristic
HIV
(n ¼ 9771),
no. (%)
No HIV
(n ¼ 5,621,817),
no. (%) P
Age group <.001
0-44 y 3278 (34) 309,509 (6)
45-54 y 3774 (39) 718,173 (13)
55-64 y 1989 (20) 1,337,328 (23)
65-74 y 628 (6) 1,783,167 (32)
75 y 102 (1) 1,473,640 (26)
Mean age, y  SD 48.9  0.28 65.6  0.05 <.001
Sex <.001
Male 7770 (80) 3,799,705 (68)
Female 2001 (20) 1,822,112 (32)
Race/ethnicity <.001
White 399 (4) 3,449,276 (61)
Black 3175 (33) 259,786 (5)
Hispanic 840 (9) 250,248 (4)
Other/missing 3606 (37) 1,662,507 (30)
Primary payer <.001
Medicare 3306 (34) 3,087,491 (55)
Medicaid 2361 (24) 258,039 (5)
Private 3101 (32) 1,963,737 (35)
Uninsured 617 (6) 163,692 (3)
Other 368 (4) 138,072 (3)
Hospital characteristics
Region <.001
Northeast 3164 (32) 1,112,977 (20)
Midwest 1079 (11) 1,372,462 (24)
South 4420 (45) 2,218,328 (40)
West 1108 (12) 918,051 (16)
Teaching status <.001
Teaching 7623 (78) 3,547,014 (63) <.001
Nonteaching 2101 (22) 2,064,089 (37)
Hospital bed size
Small 522 (5) 310,071 (6)
Medium 1724 (18) 1,071,572 (19)
Large 7479 (77) 4,229,460 (75)
SD, Standard deviation; HIV, human immunodeficiency virus.
TABLE 2. Distribution of comorbid conditions according to HIV
status
Characteristic
HIV
(n ¼ 9771),
no. (%)
No HIV
(n ¼ 5,621,817),
no. (%) P
Hypertension 4133 (42) 3,219,625 (57) <.001
Heart failure 640 (6.5) 77,505 (1.4) <.001
Peripheral arterial disease 603 (6.2) 696,943 (12) <.001
Drug abuse 1161 (12) 37,407 (0.7) <.001
Alcohol abuse 350 (3.6) 108,092 (1.9) <.001
Endocarditis 610 (6.2) 49,339 (0.88) <.001
Arrhythmia 1708 (18) 1,463,292 (26) <.001
Weight loss 370 (3.8) 96,991 (1.7) <.001
Obesity 298 (3) 488,338 (8.7) <.001
Diabetes 1489 (15) 1,296,960 (23) <.001
Diabetes þ complications 198 (2) 215,448 (3.8) <.001
Rheumatoid disease 103 (1.1) 87,371 (1.6) .068
Renal failure 1522 (16) 364,625 (6.5) <.001
Cancer 291 (3) 234,425 (4.2) .010
Lymphoma 219 (2.2) 24,059 (0.4) <.001
Anemia 1957 (20) 632,304 (11) <.001
Coagulopathy 1129 (12) 473,288 (8.4) <.001
Chronic lung disease 718 (28) 1,153,123 (21) <.001
Hypothyroidism 259 (2.7) 361,689 (6.4) <.001
HIV, Human immunodeficiency virus.
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Among the older age groups, HIVþ patients were less
prevalent (age 65-74 years, 6% HIVþ vs 32% HIV;
age>75 years, 1% vs 26%; both P<.001). Patients with
HIV undergoing cardiovascular surgery were more likely
on Medicaid (24% vs 5%) or uninsured (6% vs 3%),
and were less likely on Medicare (34% vs 55%)
(all P<.001).
Geographically, patients with HIV were more likely than
patients without HIV to be operated on in the northeast
(32% vs 20%) and the south (45% vs 40%) and less likely
in the midwest (11% vs 24%) (all P<.001). HIVþ patients
were more often treated in an academic hospital (78%
vs 63%; P < .001). The comorbid conditions among
HIVþ and HIV patients are listed in Table 2. Overall,The Journal of Thoracic and Carthe HIVþ group was sicker with a higher mean Elixhauser
comorbidity index (5.0 vs 3.8; P<.001). In addition, there
was a significantly higher proportion of endocarditis among
HIVþ patients (6.24% vs 0.88%; P<.001).
The distribution of surgeries between HIVþ and HIV
patients is shown in Figure 2. Patients with HIV were
more likely to undergo isolated valve operations (16% vs
10%), but less likely to have coronary bypass surgery
(38% vs 59%) (both P< .001). Patients with HIV also
hadmanymore cardiovascular surgeries that were classified
as other operating room heart procedure (28% vs 7%;
P < .001); most of these procedures (84%) were open
pericardial drainage operations.
Outcomes
Unadjusted outcomes between HIVþ and HIV patients
are presented in Table 3. Inpatient mortality was higher
among patients with HIV (7.2% vs 4.3%; P < .001).
Among patients undergoing cardiac surgeries exclusive of
pericardial drainage procedures, mortality was similar
between HIVþ and HIV patients (3.6% vs 4.0%;
P ¼ .432), whereas among patients undergoing only
pericardial drainage procedures, HIVþ patients had
significantly higher mortality (17.6% vs 10.7%;
P< .001). Patients with HIV also had higher rates of any
complication (40% vs 30%), blood transfusion (24% vs
19%), renal complication (10% vs 8%), and pneumonia
(11% vs 5%), but lower rates of stroke (1.2% vs 2.3%)
(all P<.001). There was no difference in rates of wounddiovascular Surgery c Volume 148, Number 6 3069
FIGURE 2. Distribution of surgeries between HIVþ and HIV patients
(P < .001). CABG, Coronary artery bypass graft; Combo, combined
surgery; HIV, human immunodeficiency virus.
TABLE 3. Unadjusted outcomes for patients with and without HIV
Variable
HIV
(n ¼ 9771)
No HIV
(n ¼ 5,621,817) P
Median length of stay,
d [15th, 85th percentiles]
9 [5, 21] 7 [4, 14] <.0001
Total charges, mean
US$  SD
110,915  3105 91,985  1190 <.0001
Total cost, mean US$  SD 42,985  1074 38,116  295 <.0001
Hospital mortality, n (%)
Overall 704 (7.2) 242,404 (4.3) <.0001
Pericardial surgeries (17.6) (10.7) <.001
Nonpericardial surgeries (3.6) (4.0) .432
Complications, n (%)
Any complication 3764 (38.5) 1,662,975 (29.6) <.001
Stroke 113 (1.2) 128,967 (2.3) <.001
Blood transfusion 2378 (24.3) 1,056,521 (18.8) <.001
Renal complication 1012 (10.4) 455,953 (8.1) <.001
Wound infection 125 (1.3) 68,094 (1.2) .794
Pneumonia 1091 (11.2) 296,141 (5.3) <.0001
Discharge disposition,
n (%)
.129
Home health care 2212 (22.6) 1,407,485 (25)
Inpatient facility 124 (1.3) 51,111 (0.9)
Other transfer 1959 (20) 1,407,485 (19.5)
Routine/home transfer 5455 (55.8) 3,056,676 (54.4)
SD, Standard deviation; HIV, human immunodeficiency virus.
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Dinfection. The median length of stay was longer for HIVþ
patients (9 days [15th percentile, 5 days; 85th percentile,
21 days] vs 7 days [15th percentile, 4 days; 85th percentile,
14 days]; P<.001), and mean total cost was higher among
HIVþ patients (US$42,985  1074 vs US$38,116  295;
P< .001). There was no difference in disposition: home
versus home with home health care versus transfer to
another inpatient facility or other facility.
Outcomes between HIVþ and HIV patients after
propensity-score matching are displayed in Table 4. TheFIGURE 3. Trends in incidence of death (P ¼ .021), complications
(P ¼ .035), and endocarditis (P ¼ .672) among patients with HIV
undergoing cardiovascular surgery during the study period. HIV, Human
immunodeficiency virus.
3070 The Journal of Thoracic and Cardiovascular Sureffect of HIV status on selected outcomes after
propensity-score matching is shown in Table 5. Patients
with HIV were at no increased risk for inpatient mortality
(odds ratio [OR], 0.98; confidence interval [CI], 0.74,
1.30). Patient with HIV infection were more likely to
receive a blood transfusion (OR, 1.19; CI, 1.01, 1.40) and
have any postoperative complication (OR, 1.16; CI, 1.01,
1.34), but less likely to suffer a postoperative stroke
compared with those without HIV (OR, 0.43; CI, 0.25,
0.74). There was no difference in rates of pneumonia, renal
complications, or wound infections. The median length of
stay was not different between the groups (HIVþ, 8 days
[15th percentile, 5 days; 85th percentile, 20 days]; HIV,
7 days [15th percentile, 4 days; 85th percentile, 18 days];
P ¼ .060), nor was the mean total cost (HIVþ,
US$41,157 33,916; HIV, US$42,496 41,195;P¼ .7).
Trends in cardiac surgery outcomes among patients with
HIV infection are shown in Figure 3. Between 1998 and
2009, there was a significant decline in the adjusted
inpatient mortality rate from 6% to 0.7% (P ¼ .021); the
adjusted composite rate of any complication increased
from 40% to 54% (P¼ .035). During the same time period,
the incidence of endocarditis among patients with HIV
infection declined from 6.9% to 4.0% (P ¼ .672).
Among patients with HIV, metastatic cancer, coagulop-
athy, renal failure, and surgery type (aortic, other, or
combined surgical procedure compared with CABG)
resulted in an increased risk of death; the presence ofgery c December 2014
TABLE 4. Risk-adjusted outcomes for patients with and without HIV
among propensity-matched pairs
Variable
HIV
(n ¼ 1633)
No HIV
(n ¼ 1633) P
Median length of stay,
d [15th, 85th percentiles]
8 [5, 20] 7 [4, 18] .060
Total charges, median US$ 77,661 77,290 .006
Total cost, median US$ 32,413 31,125 .700
Hospital mortality, n (%)
Overall 100 (6.1) 102 (6.2) .915
Pericardial surgeries (17.0) (16.3) .905
Nonpericardial surgeries (3.4) (4.8) .068
Complications, n (%)
Any complication 597 (36.6) 541 (33.1) .038
Stroke 20 (1.2) 45 (2.8) .001
Blood transfusion 382 (23.4) 334 (20.5) .047
Renal complication 145 (8.9) 151 (9.2) .791
Wound infection 24 (1.5) 31 (1.9) .313
Pneumonia 156 (9.6) 129 (7.9) .086
Discharge disposition, n (%) .801
Home health care 381 (23.3) 368 (22.5)
Inpatient facility 20 (1.2) 23 (1.4)
Other transfer 283 (17.3) 267 (16.4)
Routine/home transfer 946 (57.9) 973 (59.6)
HIV, Human immunodeficiency virus.
TABLE 6. Risk factors for death among HIVþ patients
Variable Adjusted odds ratio (95% CI)
Total no. of patients 9771
Metastatic cancer 3.1 (1.6-6.0)
Coagulopathy 2.7 (1.7-4.3)
Renal failure 1.6 (1.0-2.4)
Type of operation*
Aortic 6.5 (2.9-14.5)
Other 8.8 (4.5-17.1)
Combined 2.7 (1.1-6.6)
CI, Confidence interval. *Compared with coronary artery bypass graft.
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Danemia led to a decreased risk of death. Hospital size,
insurance status, and academic affiliation did not affect
mortality risk (Table 6).
DISCUSSION
Significant improvements in medical therapy have
allowed patients with HIV to live much longer. However,
the use of protease inhibitors has likely amplified cardiac
complications both directly and indirectly. As a direct result
of improved survival with HAART, patients with HIV are
living longer and are more likely to develop chronic cardio-
vascular diseases such as CAD, aortic pathology, and aortic
stenosis.15 In addition, these drugs seem to have pleotropic
effects leading to increased risk for cardiac problems.
In the 2007 Data Collection on Adverse events of Anti-
HIV Drugs group study of 24,437 HIVþ patients, theTABLE 5. Effect of HIV status on propensity-matched outcomes
Variable Adjusted odds ratio (95% CI)
Total no. of patients 3266
Mortality 0.98 (0.74-1.30)
Complications
Any complication 1.16 (1.01-1.34)
Stroke 0.43 (0.25-0.74)
Blood transfusion 1.19 (1.01-1.40)
Wound infection 0.77 (0.45-1.32)
Renal complication 0.96 (0.75-1.22)
Pneumonia 1.24 (0.97-1.58)
CI, Confidence interval.
The Journal of Thoracic and Carrelative rate of MI per year of exposure to protease
inhibitors was 1.16.7 Thus, it seems that protease inhibitors
predispose patients to develop metabolic syndrome, which
then may increases the risk of accelerated cardiovascular
disease at a much earlier age. However, we found that
HIVþ patients were less likely to have CABG operations.
Pearce and colleagues16 have shown an increased mortality
burden and lower procedural (both percutaneous coronary
intervention and CABG) rates in HIVþ patients receiving
care for acute MI, suggesting that there may be some
element of discrimination in processes of care among
HIVþ patients with acute MI.16 We observed an unadjusted
mortality rate of 7.2% in the HIVþ patients. This was
driven in large part by HIVþ patients undergoing pericar-
dial drainage procedures and they likely had more advanced
disease.
Other studies have examined the outcomes of cardiac
surgery in HIVþ patients.17-19 Most are case studies or
small single-institution reviews that, like our study, showed
good outcomes with lowmortality. In a retrospective review
of 37 HIVþ patients Trachiotis and colleagues20 reported
acceptable outcomes (2.7% mortality rate) and low
complication rates (sepsis 5.4%, deep sternal infection
2.7%, bleeding 5.4%, and prolonged intubation 5.4%).
Freedom from death, angina, MI, repeat revascularization,
and congestive heart failure at 3 years was 81%. In 2008,
a case-control study of 27 HIVþ patients undergoing
CABG showed no difference in 30-day rates of postopera-
tive death, MI, stroke, mediastinitis, or reintervention
compared with HIV patients. At a mean follow up of 41
months, HIVþ patients were more likely to experience
death from a cardiac cause, have an MI, or undergo
coronary revascularization compared with HIV patients
(42% vs 25%; P ¼ .03).21 In this national series, we noted
some differences in the regional rates of cardiac operations
in HIVþ patients. Rates were higher in the northeast and
south. This mirrors the general incidence of HIV disease;
the northeast has 24% of new cases of HIV and the south
has 45%.22
Although most studies have focused on CAD and CABG
operations, we observed that HIVþ patients were more
likely to undergo valve surgery than HIV patients.diovascular Surgery c Volume 148, Number 6 3071
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of infective endocarditis associated with immunosuppres-
sion and/or intravenous drug use. In a retrospective review
of valve surgery in 22 HIVþ patients between 1990 and
1999, the most common indications for surgery were sepsis
in 91% and heart failure in 59%. Staphylococcal infections
were responsible for 43% of cases and Streptococcus
made up 29%; Pseudomonas and Haemophilus species
accounted for 4% each. Twelve patients underwent aortic
valve replacement, 7 had mitral valve replacement, and 3
had double valve replacement. There were no operative or
in-hospital deaths, and 5-year survival was 55%.23 This is
a great improvement over early series that reported
operative mortalities of more than 20%.11,24 Over time,
however, endocarditis has become less common as
HAART therapy and antibiotic prophylaxis have
improved and the burden of chronic diseases has
increased by way of increased life expectancy.25 In
addition, the metabolic syndrome seen in patients on
protease inhibitors may also contribute to early degenera-
tive valve disease. With regards to disease of the aorta, there
is no clear understanding of the predisposing factors,
although accelerated atherosclerosis and vasculitis may
play a role. Vasculitis involving the aorta in HIVþ patients
has been reported. Pathologic examinations reported from
small studies have shown leukocytoclastic vasculitis of
the vasa vasorum as a potential cause of aortic disease in
HIVþ patients.26
A recent study examining the outcomes of HIVþ patients
undergoing cardiac operations also used the NIS dataset.27
They examined clinical outcomes and trends from 2000 to
2010 in patients undergoing CABG and valve surgery.
Overall, their results are similar to ours, but the rates of
endocarditis were reported to have decreased substantially
over the study period, from about 30% to less than 10%.
We did not observe this trend and this may be due to the
method used to query the NIS database. A study of
infectious endocarditis in the United States showed that
4.8% of patients with endocarditis were HIVþ in 1998
compared with only 1.5% in 2009.25 Furthermore, we
have included propensity matching in the current study.
This is important as patients with HIV tend to present at a
younger age and should be compared with similar patients
in order to understand the real outcomes. In addition,
we were interested in morbidity outcomes and resource
utilization after cardiovascular surgeries.
Overall, mortality for HIVþ patients decreased over the
course of the study period. However, the rate of morbidity
increased. We hypothesize that patients who may have
died previously are now surviving, albeit with more
complications. The component that leads to most of the
complications after cardiac surgery in HIVþ patients is
blood transfusion. Our observation that HIVþ patients
were more likely to have blood transfusion is important as3072 The Journal of Thoracic and Cardiovascular Surwe have shown that this increases the likelihood of
infections such as pneumonia, and in an already immuno-
compromised population, this may lead to more late
complications that may not be apparent in a discharge-
level database such as the NIS.18 HIVþ patients are likely
receiving more blood transfusions because they have a
much higher rate of anemia preoperatively. Anemia is the
most common hematologic disorder in patients with HIV.
Anemia in HIVþ patients has been shown to be caused
by suppressed erythropoiesis and altered iron metabolism
caused by inflammation, iron and folate deficiency, some
types of chemotherapeutic drugs, race, sex, and the virus
itself.28 It will certainly be important to understand the
long-term implications of blood transfusions in this patient
population in order to make the best recommendations for
treatment of anemia.
In our sample, fewer patients with HIV had a postopera-
tive stroke than similar HIV patients. This is interesting
because patients with HIV are known to have higher
rates of ischemic and hemorrhagic stroke compared with
age- and sex-matched HIV patients. Lower rates of
postoperative atrial fibrillation, common among HIVþ
patients, may explain our observed lower rate of stroke.29
Unfortunately, we could not reliably determine the rates
of postoperative atrial fibrillation from the NIS dataset.
This study provides a good understanding of the trends in
cardiovascular operations for patients with HIV, but there
are limitations to our work. The NIS is an administrative
database, based on administrative data, and does not
provide clinical information such as CD4 count or viral
load. Observing that HIVþ patients are at risk for blood
transfusions and any complication is important, but without
accompanying clinical information, it is not possible to
surmise the reasons for this or how the situation can be
remedied. However, it may be prudent to address any
modifiable risk factors preoperatively. Furthermore, the
data are limited to events that occurred during the initial
hospitalization, without information on delayed complica-
tions or readmissions. Despite these limitations, this
database provided access to millions of operations and is
probably most useful for this type of situation: to under-
stand the trends of a clinical entity that is uncommon and
where no single institution has a large experience. Multiple
studies have used the NIS database to evaluate outcomes,
epidemiology, and utilization in cardiac surgery. Because
HIVþ patients are typically younger than 65 years of age,
datasets such as the Medicare 5% national sample may
not be applicable.
In conclusion, the treatment of HIV has prolonged the life
of millions of patients, but the extension of life and the
drugs used to achieve it come with the price of increased
cardiovascular disease. In this study, we have shown that
cardiovascular surgery can be performed safely for patients
with HIV with no increase in resource utilization orgery c December 2014
Robich et al Acquired Cardiovascular Diseasepostoperative complications aside from increased need for
blood transfusion. Patients with HIV should not be denied
an indicated cardiovascular surgery just because of their
disease. Optimizing control of HIV preoperatively by
ensuring low viral loads, reasonable immune reconstitution,
and treatment of anemia may also help improve outcomes.
There was a time when discussion of the chronic diseases of
HIV patients was considered unnecessary, but with HAART
therapy that has changed. Patients are living longer and
we should expect to see more of these patients needing
cardiovascular operations.A
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Dr Hossein Almassi (Milwaukee, Wis). Nice presentation. This
is a timely presentation, long overdue. I still remember a time
when a member of this association in Wisconsin announced to
the public that he would not operate on HIV-positive patients
needing cardiac operations. Of course, we have come a long
way since then, and a lot of progress has been made as we heard
from Dr Robich in his presentation today.
With HAART therapy, patients survive long with their chronic
disease, and as cardiac surgeons, we are going to see more of this
baby boomer generation with HIV requiring cardiac surgery.
The study is an analysis of a large administrative database over a
10-year period. It provides some important information; although,
it suffers from the lack of patient level data, and you have admitted
that in your manuscript. Information such as the stage of the HIV,
the level and the length of the antiretroviral therapy, indications for
surgery, urgency of the operation, and some other information are
lacking.
The patients with HIV were younger than the non-HIV group
with a higher rate of renal failure and liver disease but with no
increase in renal complications postoperatively, but I will get to
that later on.
And as you mentioned, CABG was the predominant operation
in close to 40% of the patients. In propensity-matched patients,
HIV-positive status had no impact on in-hospital mortality, but
postoperative complications and the need for blood transfusions
were significantly higher in this cohort of patients, yet there was
no difference in costs between the 2 groups. That is interesting
to see.
Dr Robich, I have 3 questions. I am going to ask you 1 at a time.
Preoperative renal failure was a risk factor for mortality in
HIV-positive patients, but the rate of postoperative renal failurediovascular Surgery c Volume 148, Number 6 3073
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patients.
Was the high rate of renal failure preoperatively distributed
evenly throughout the study period, or was it more concentrated
in the earlier period of this study? And if so, did you notice a
difference between the outcomes of patients in the earlier part of
this study versus the latter part of this study?
Dr Robich. That is a very good question. Thank you,
Dr Almassi, for reading our manuscript and discussing our talk.
To answer the first question, the rates of renal failurewere pretty
steady throughout the study period. We did not see any large
increase in renal failure over the course of the study period.
Dr Almassi. Could you tell us why patients with HIV require
more blood transfusions, and you alluded to it that they did. I noted
in your slides that the postoperative anemia was more prevalent in
HIV-positive patients.
What would happen if you did a separate analysis excluding
the anemic patients? Would the difference for the increase in
transfusion rate still be significant, and if so, could you elaborate
on the reasons for this increased need for blood transfusion in these
patients?
DrRobich. That is an excellent question. So the level of anemia
we think is probably due in some part obviously to their HIV.
We did not do that analysis of looking at it without the blood
transfusion. But my suspicion is, if we did do that, that the
significant increase that we saw in any complication rates would
no longer be there.
And then the other part of your question was regarding whether
or not..
Dr Almassi.. you should do a separate analysis excluding the
anemic patients, preoperative anemia. Would still the difference in
transfusion be significant?
Dr Robich. Right. That is a good question. We did not look
at that either, and I actually do not know the answer to that. I am
not sure if it would or not. I assume it would, but I do not know.
Dr Almassi. My last question is regarding the complication
rate. I think you partially answered that; that it was higher in
HIV-positive patients. It was interesting that it was increasing
throughout the study period over the 10 years.
Did you look at the components of these morbidities to see what
the predominant contributors other than anemia are? Because I
think that is important information for treating physicians to figure
out what to do with those factors so that the complication rate will
drop down because clearly the mortality has dropped, but the
complication rate is going in the opposite direction.
Dr Robich. That is exactly right.
Dr Almassi. Nice presentation. I enjoyed your presentation.
Dr Robich. Thank you very much.
So to answer your question, I think 1 of the things that. I am
sorry, I lost my train of thought. Your question again was
regarding?
Dr Almassi. Components of the morbidities other than anemia.
Dr Robich. Oh, right. I am sorry.
Dr Almassi. Have you looked at the components of morbidity
to see what they are, the significant contributors of this
increasing rate of morbidities so that then surgeons and physicians
can deal with it and to come up with strategies to take care of
those?3074 The Journal of Thoracic and Cardiovascular SurDrRobich.Right. I think 1 of the reasons that we saw increased
complication rates and lower mortality is that there probably were
patients in the past who were dying, and because of better care, we
were able to rescue them from death. And, unfortunately, they
probably suffered more complications as they may have died
before, but now they have a complication. That is 1 reason.
The second thing that is interesting is there are several
modifiable risk factors that I did not present today but that we
have noticed and that would be important. One of the things that
we found would be the coagulopathy. I think if we address that
and if we maximize the therapy for their HIVand address any fluid
and electrolyte imbalances, those were all risk factors as well for
complications.
So I think there are modifiable risk factors we can address to
further improve outcomes.
Dr Charles M. Geller (New York, NY). Thank you for this
thought-provoking presentation. Having had the opportunity to
operate on many HIV-positive patients each year for the past 2
decades, I believe that all immunodeficient patients are not alike.
Were you able to determine either a viral load level or a
CD4/T-cell count cutoff level at which outcomes in this patient
population were affected?
Dr Robich. That is an excellent question and I think a critical
thing to understand. Unfortunately, this database does not have
that type of clinical data in it, so we do not know what their
CD4 status was. But I think that is an important point.
Dr Mark S. Slaughter (Louisville, Ky). Along those same
lines, there is a difference between being HIV-positive and having
AIDS, so your risk of other, which was essentially open pericardial
windows and cancer, are those just surrogate markers for patients
who have systemic disease and significant immunosuppression?
Dr Robich. That is an excellent point. That is our belief that
these patients are probably a lot more advanced in their disease,
may not have had adequate medical treatment beforehand, and I
would agree with that.
Dr Slaughter. Lastly, you made the comment that there were
fewer strokes, and you believed this was due to the immunomodu-
lation. Predominantly and particularly in coronary surgery, it is an
embolic event related to the atherosclerotic load.
So what immunomodulating effect decreases the atheroscle-
rotic load in these patients?
Dr Robich. Well, that is a good question as well, and I do not
know if it is completely due to the immunomodulation or
decreasing inflammation in general.
And also, as I pointed out, they had less peripheral arterial
disease, and it may be just a factor of them being younger and
not having developed a heavy atherosclerotic burden at this point.
Dr Giuseppe D’Ancona (Palermo, Italy). You mention valve
operations. I was wondering, do you have any specific data about
HIV-positive patients who are drug addicts and the recurrence of
endocarditis or infection because I would presume that then the re-
sults are somewhat different.
Dr Robich. Well, that is true. And about 6% of the patients in
our study over the entire period had endocarditis. However, we
did not look at them separately, endocarditis versus nonendocardi-
tis valve operations, but certainly that would likely have an impact.
Dr Edward G. Soltesz (Cleveland, Ohio). So when we did this
analysis, we actually did the analysis with smaller subgroups asgery c December 2014
Robich et al Acquired Cardiovascular Diseasewell. We did subgroup analysis of only doing CABG, isolated
CABG, isolated valve aortic surgery only, thoracic aortic surgery.
We get a smaller number obviously, but the outcomes are exactly
the same.
We included the larger group practice, including those other
cardiovascular surgeries, mainly open pericardial drainages,
because that is sort of our practice in our entire department. And
we figured because we are going to see them, these types of
patients, we want to sort of know what their outcomes are going
to be in general.
The second issue is to comment on the stroke. So it is very
interesting. In HIV patients as a whole, the incidence of
ischemic stroke and hemorrhagic stroke is increasing, but theThe Journal of Thoracic and Carincidence of atrial fibrillation is lower. So you could potentially
make the connection that these patients, although we cannot
necessarily determine this from this database, that they have less
postoperative atrial fibrillation, and as you said, less embolic
events.
Dr Frank W. Sellke (Providence, RI). I think another way to
look at that is people with HIV may have less of an inflammatory
response, and with the same atherosclerotic burden or emboli, you
do not have the inflammatory influence to propagate the stroke.
And the same thing with atrial fibrillation. You have less
inflammation, so you may have less atrial fibrillation because of
that reason.
Dr Robich. I would agree with that, Dr Sellke.diovascular Surgery c Volume 148, Number 6 3075
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